NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (ICPT, Financial), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that management will be presenting at the following upcoming investor conference:
- 37th Annual J.P. Morgan Healthcare Conference at 2:30 p.m. PT on Wednesday, January 9, 2019.
Webcast information for this event will be available on the investor page of Intercept’s website at http://ir.interceptpharma.com. An archived webcast will be available on Intercept’s website for approximately two weeks.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New York, Intercept has operations in the United States, Europe and Canada.
CONTACT
For more information about Intercept, please contact:
Mark Vignola
+1-646-747-1000
[email protected]
Media inquiries: [email protected]
